Epidemiology and mechanisms of resistance: Clinical and environmental impact;Epidemiologia e meccanismi di induzione di resistenza batterica: Impatto clinico e ambientale

Infezioni in Medicina

Volumn 15, Issue SUPPL. 2, 2007, Pages 6-12

  Drago, Lorenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Bacterial resistance; Sinergy

Indexed keywords

ACYLTRANSFERASE; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; ENVIRONMENTAL IMPACT; GENETIC VARIABILITY; INFECTION; INFECTION CONTROL; SANITATION;

BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MUTATION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 36049030734     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. D'Costa V.M., McGrann K.M., Hughes D.W., Wright G.D. Sampling the antibiotic resistome. Science 311, 5759, 374-377, 2006.
2. Wright G.D. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat. Rev. Microbiol. 5, 3, 175-186, 2007.
3. Levin B.R., Rozen D.E. Non-inherited antibiotic resistance. Nat. Rev. Microbiol. 4, 7, 556-562, 2006.
4. Robicsek A., Strahilevitz J., Giacoby G.A., et al. Fluoroquinolone- modifying enzyme: a new adaption of a common aminoglicoside acetyl-transferase. Nature Medicine, 2006, 12, 83-88.
5. Felmingham D., Gruneberg R.N. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project. J. Antimicrob. Chemother. 38, Suppl A, 1-57, 1996.
6. Felmingham D., Gruneberg R.N. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J. Antimicrob. Chemother. 45, 2, 191-203, 2000.
7. Schito G.C., Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). Int. J. Antimicrob. Agents. 26, 6, 479-485, 2005.
8. Karlowsky J.A., Kelly L.J., Thornsberry C., et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. Int. J. Antimicrob. Agents. 19, 1, 21-31, 2002.
9. Karlowsky J.A., Jones M.E., Thornsberry C., Evangelista A.T., Yee Y.C., Sahm D.F. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin. Infect. Dis. 40 Suppl 2, S89-98, 2005.
10. Segatore B., Setacci D., Perilli M., et al. Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43, 2, 428-431, 1999.
11. Drago L., De Vecchi E., Mombelli B., Nicola L., Valli M., Gismondo M.R. Activity of levofloxacin and ciprofloxacin against urinary pathogens. J. Antimicrob. Chemother. 48, 1, 37-45, 2001.
12. De Vecchi E., Drago L., Nicola L., et al. Resistenza di Pseudomonas aeruginosa a ciprofloxacina e levofloxacina negli anni 1998-2002. In Program and Abstracts of the 6th IBAT, Naples (Italy) 2003, abstract p 198.
13. Cosentini R., Tarsia P., Blasi F., Roma E., Allegra L. Community-acquired pneumonia: role of atypical organisms. Monaldi Arch. Chest. Dis. 56, 6, 527-534, 2001.
14. Black R.E., Craun G.F., Blake P.A. Epidemiology of common-source outbreaks of shigellosis in the United States, 1961-1975. Am. J. Epidemiol. 108, 1, 47-52, 1978.
15. Espinal M.A., Kim S.J., Suarez P.G., et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283, 19, 2537-2545, 2000.
16. Fridkin S.K., Gaynes R.P. Antimicrobial resistance in intensive care units. Clin. Chest. Med. 20, 2, 303-316,1999.
17. Holmberg S.D., Wells J.G., Cohen M.L. Animal-to-man transmission of antimicrobial-resistant Salmonella: investigations of U.S. outbreaks, 1971-1983. Science 225, 4664, 833-835, 1984.
18. Kopp B.J., Nix D.E., Armstrong E.P. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann. Pharmacother. 38, 9, 1377-1382, 2004.
19. McMaster P., McIntyre P., Gilmour R., Gilbert L., Kakakios A., Mellis C. The emergence of resistant pneumococcal meningitis-implications for empiric therapy. Arch. Dis. Child. 87, 3, 207-210, 2002.
20. Paris M.M., Ramilo O., McCracken G.H. Jr. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 39, 10, 2171-2175, 1995.
21. Swartz M.N. Bacterial meningitis-a view of the past 90 years. N. Engl. J. Med. 351, 18, 1826-1828, 2004.
22. Lujan M., Gallego M., Fontanals D., Mariscal D., Rello J. Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit. Care Med. 32, 3, 625-631, 2004.
23. Damas P., Canivet J.L., et al. Selection of resistance during sequential use of preferential antibiotic classes. Intensive Care Med. 32, 1, 67-74, 2006.
24. Ba B.B., Feghali H., Arpin C., Saux M.C., Quentin C. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob. Agents Chemother. 48, 3, 946-953, 2004.
25. De Vecchi E., Nicola L., Gismondo M.R., Drago L. A comparative in vitro evaluation of resistance development after exposure to teicoplanin, vancomycin, linezolid and quinupristin/dalfopristin in Staphylococcus spp. and Enterococcus spp. in Program and Abstracts 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France, April 1-4 2006 (Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006).
26. Timurkaynak F., Can F., Azap O.K., Demirbilek M., Arslan H., Karaman S.O. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents. 27, 3, 224-228, 2006.
27. Zhanel G.G., Mayer M., Laing N., Adam H.J. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50, 6, 2228-2230, 2006.
28. Drago L., De Vecchi E., Nicola L., Tocalli L., Gismondo M.R. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. J. Antimicrob. Chemother. 56, 2, 353-359, 2005.
29. Chait R., Craney A., Kishony R. Antibiotic interactions that select against resistance. Nature 446, 7136, 668-671, 2007.